Chao Han
Nanjing University
5 Papers
Chao Han is an academic researcher from Nanjing University. The author has contributed to research in topics: Biology & Medicine. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Chloroquine enhanced the anticancer capacity of VNP20009 by inhibiting autophagy
Xiaoxin Zhang,Qiaoqiao Xu,Zhuangzhuang Zhang,Wei Cheng,Wenmin Cao,Chizhou Jiang,Chao Han,Jiahuang Li,Zi-Chun Hua,Zi-Chun Hua,Zi-Chun Hua +10 more
TL;DR: The results showed that the combined therapy of VNP20009 and chloroquine could significantly inhibit tumor growth and prolong mouse survival time, providing a novel strategy for improving the anti-cancer efficacy of bacterial cancer therapy.
18
Neutrophil‐Mediated Tumor‐Targeting Delivery System of Oncolytic Bacteria Combined with ICB for Melanoma Lung Metastasis Therapy
Lina Liu,Wenjie Xin,Qiang Li,Baolian Huang,Tengfei Yin,Siqi Hua,Chen-Xi Yang,Chen Chen,Chao Han,Zi-Chun Hua +9 more
TL;DR: A delivery system with controlled release of V NP after being loaded into neutrophils, which significantly increases the tumor‐targeting of VNP and enhances its therapeutic efficacy in a melanoma lung metastasis model is constructed.
14
The genes slyA, STM3120 and htrA are required for the anticancer ability of VNP20009
Xiaoxin Zhang,Qiaoqiao Xu,Lirun Yang,Yueyang Lai,Zhuangzhuang Zhang,Chao Han,Chizhou Jiang,Jiahuang Li,Yixin Shi,Zi-Chun Hua +9 more
TL;DR: The results indicate that the immune responses elicited by bacteria rather than the bacterial titer in tumors play a “decisive” role in VNP20009-mediated bacterial cancer therapy, which provides a novel perspective for the underlying mechanism of bacterial cancer Therapy.
Bacteria-mediated tumor-targeted delivery of tumstatin (54-132) significantly suppresses tumor growth in mouse model by inhibiting angiogenesis and promoting apoptosis
Feifei Bao,Mengchun Liu,Wenhua Gai,Yuwei Hua,Jing Li,Chao Han,Ziyu Zai,Jiahuang Li,Zi-Chun Hua +8 more
TL;DR: This study is the first to use tumstatin-transformed VNP20009 as a tumor-targeted system for treatment of melanoma by combining anti-tumor and anti-angiogenic effects.